Meds Apotek AB (STO:MEDS)
Sweden · Delayed Price · Currency is SEK 25.30
-0.30 (-1.17%)
At close: Sep 2, 2026
Meds Apotek AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,080 | 1,006 | 829.23 | 655.2 | 609 | 193.09 | |
Revenue Growth | 16.37% | 21.37% | 26.56% | 7.59% | 215.40% | -15.86% |
Cost of Revenue | 837.24 | 778.45 | 640.73 | 534.23 | 455.55 | 148.21 |
Gross Profit | 242.55 | 227.94 | 188.5 | 120.97 | 153.45 | 44.88 |
Selling, General & Admin | 231.88 | 221.79 | 183.89 | 154 | 72.98 | 25.54 |
Other Operating Expenses | -12.59 | -11.63 | -7.99 | -4.39 | 171.58 | 60.2 |
Operating Expenses | 237.9 | 230.35 | 196.65 | 170.24 | 260.01 | 89.01 |
Operating Income | 4.65 | -2.41 | -8.16 | -49.28 | -106.57 | -44.13 |
Interest Expense | -0.52 | -1.03 | -3.91 | -3.81 | -1.17 | -0.35 |
Interest & Investment Income | 0.55 | 0.43 | 0.95 | 1.44 | - | - |
Currency Exchange Gain (Loss) | - | - | - | 0.16 | - | - |
Other Non Operating Income (Expenses) | -0 | -0 | - | 0 | - | - |
Pretax Income | 4.67 | -3 | -11.11 | -51.48 | -107.74 | -44.47 |
Income Tax Expense | -10.29 | -10.73 | -0.71 | -0.46 | 1.77 | 0.34 |
Earnings From Continuing Operations | - | 7.73 | -10.4 | -51.02 | -109.51 | -44.81 |
Net Income to Company | - | 7.73 | -10.4 | -51.02 | -109.51 | -44.81 |
Net Income | 14.96 | 7.73 | -10.4 | -51.02 | -109.51 | -44.81 |
Net Income to Common | 14.96 | 7.73 | -10.4 | -51.02 | - | - |
Net Income Growth | 455.63% | - | - | - | - | - |
Shares Outstanding (Basic) | 18 | 18 | 17 | 17 | - | - |
Shares Outstanding (Diluted) | 19 | 18 | 17 | 17 | - | - |
Shares Change | 8.48% | 3.40% | 2.98% | - | - | - |
EPS (Basic) | 0.82 | 0.44 | -0.60 | -3.05 | - | - |
EPS (Diluted) | 0.81 | 0.43 | -0.60 | -3.05 | - | - |
EPS Growth | 420.34% | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 8.23 | -21.83 | 19.84 | -49.78 | - | - |
Free Cash Flow Per Share | 0.44 | -1.22 | 1.15 | -2.97 | - | - |
Gross Margin | 22.46% | 22.65% | 22.73% | 18.46% | 25.20% | 23.24% |
Operating Margin | 0.43% | -0.24% | -0.98% | -7.52% | -17.50% | -22.85% |
Profit Margin | 1.39% | 0.77% | -1.25% | -7.79% | - | - |
Free Cash Flow Margin | 0.76% | -2.17% | 2.39% | -7.60% | - | - |
EBITDA | 6.61 | -0.28 | -5.96 | -46.94 | -91.11 | -40.86 |
EBITDA Margin | 0.61% | -0.03% | -0.72% | -7.16% | -14.96% | -21.16% |
D&A For EBITDA | 1.96 | 2.12 | 2.19 | 2.33 | - | - |
EBIT | 4.65 | -2.41 | -8.16 | -49.28 | -106.57 | -44.13 |
EBIT Margin | 0.43% | -0.24% | -0.98% | -7.52% | -17.50% | -22.85% |
Revenue as Reported | 1,093 | 1,018 | 837.39 | 659.97 | - | - |